AMRA-MEDICAL
2.5.2024 15:36:33 CEST | Business Wire | Press release
AMRA Medical - a health informatics and precision medicine company that is pioneering body composition research through gold-standard MRI-based analysis platforms - collaborated on a study driven by University of Texas Southwestern and University Hospital Cleveland to publish new data revealing the effect of liraglutide treatment on muscle composition in adults with obesity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502719692/en/
Credit: Collaboration with Dr. Ian J Neeland, University Hospitals Cleveland. Data from NCT03038620 (ClinicalTrials.gov identifier) analysed with AMRA® Researcher
The analysis included 128 diabetes-free adults with obesity who received a lifestyle intervention in addition to being randomized to either a liraglutide (n = 73) or a placebo (n = 55) treatment group. Using the proprietary MRI-based AMRAⓇ Researcher, baseline and follow-up muscle composition analyses were performed, with the primary objective of assessing change in thigh muscle fat infiltration due to treatment intervention over a 40-week period. Participants were also assessed for the exploratory outcome of adverse muscle composition, defined as high muscle fat infiltration and low muscle volume z-score.
Among the 128 participants, median muscle fat infiltration at baseline was 7.8%. The study found that liraglutide significantly reduced muscle fat infiltration when compared to placebo. The mean percent change in muscle fat infiltration for those randomized to liraglutide was -2.87% from baseline, and 0.05% in the placebo arm (absolute change: -0.23% vs. 0.01%). Additionally, a weight-invariant assessment of muscle volume was performed using AMRA’s muscle volume z-score did not show a significant reduction comparing liraglutide to placebo (mean treatment difference adjusted for baseline muscle volume z-score was -0.08 standard deviations). The study also uncovered that the proportion of participants with adverse muscle composition dropped from 11.0% to 8.2% over follow-up in the liraglutide arm, while no change in the placebo arm was observed.
While the contribution of muscle fat infiltration improvement to the cardiometabolic benefits of liraglutide requires further investigation, the above findings come at a critical time given the global rise of obesity incidence and its comorbidities posing more of a threat to patients than ever before. As the treatment paradigm begins to shift from solely lifestyle changes to one that includes pharmacological intervention (namely the popular GLP-1 agonists such as liraglutide) and drug development in obesity ramps up, it is paramount that these drugs are accurately assessed for their impact on muscle composition to ensure that the weight loss they help to achieve does not result in adverse effects on muscle health.
Through their gold-standard MRI-based body composition analysis technology, AMRA is committed to pioneering the creation of normative datasets explaining the effect of GLP-1s and incretin-based treatments on muscle composition to help the obesity field gain further insight as to how these drugs work in this relatively new indication. Recently, AMRA presented related findings at the 59th European Association for the Study of Diabetes Annual Meeting, where it was shown that another popular GLP-1, tirzepatide, achieved significant weight loss without any adverse effects on muscle composition. You can view the presentation here.
Learn more about AMRA Medical and how the use of MRI-based body composition analysis is advancing disease research in metabolic diseases including obesity, and beyond.
About AMRA Medical
AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans. AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via their innovative platform.
Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions, or connect with our team of experts for a detailed discussion at info@amramedical.com.
Follow AMRA on LinkedIn for the latest updates in body composition and precision medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502719692/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom